Enasidenib Active, Well Tolerated in Small Cohort of MDS Patients With IDH2 Mutation

December 3-6, 2016; San Diego, California
Daily oral enasidenib monotherapy shows activity in a small cohort of patients with predominately high-risk mIDH2 MDS, including some who failed prior HMA treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 498 KB
Released: December 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of complement inhibition in patients with ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue